Penumbra (PEN)
(Delayed Data from NYSE)
$234.36 USD
+12.21 (5.50%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $234.45 +0.09 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
PEN 234.36 +12.21(5.50%)
Will PEN be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for PEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PEN
Penumbra (PEN) Gains From Innovation, Mounting Costs Ail
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
PEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
Penumbra (PEN) Q4 Earnings Top Estimates, Margins Increase
Penumbra (PEN) Q4 Earnings Beat Estimates
Other News for PEN
PBF Energy (PBF) Gets a Hold from Piper Sandler
Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now
Penumbra’s Growth Trajectory and Market Dominance Reinforce Buy Rating
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Jazz Pharmaceuticals (JAZZ) and Argenx Se (ARGX)
Piper Sandler cuts Inari to neutral; cites slowing growth, DOJ probe